SSSS had positive anti-Dsg1 IgG by ELISA as well as immunoblotting, although serum was obtained only at day 6 (SSSS no. 6 in Table 2 ). No antiDsg3 IgG was detected either by ELISA or by immunoblotting in these patients studied throughout their course, indicating the specificity of the reactivity against Dsg1 (Table 1) . No apparent IgM reactivity against Dsg1 or Dsg3 was detected by ELISA (data not shown). None of the 12 patients with BI, whose sera were taken with a range of days 2-33, showed any detectable IgG production against either Dsg1 or Dsg3 as determined by ELISA and immunoblotting (Table 1) .
These findings indicate that a small number of patients of SSSS develop low titers of IgG antibodies specific for Dsg1 after binding and systemic digestion of Dsg1 by staphylococcal ETs. This observation is specific for patients with SSSS because none of the patients with BI showed any sign of anti-Dsg1 antibody production. This may be because a single episode of BI may be too limited to cause an immune response. Although none of these patients develop PF after SSSS, which is not known as a predisposing factor for PF, the findings presented here provide evidence that infection which modifies self-antigen can trigger the production of IgG autoantibodies against the self-antigen.
Of course, these patients do not develop clinically overt PF. We would speculate that other genetic or environmental factors are needed to extend the immune response to encompass pathogenic antibodies and to produce overt clinical PF. For example, in the endemic form of PF, fogo selvagem, that is found in rural areas of South America, it might be possible that repeated modification of Dsg1 by chronic or recurrent staphylococcal infection in genetically susceptible individuals might trigger disease.
Thus, our data are consistent with the hypothesis that a bacterial toxin can modify a self-antigen to result in an autoantibody response. The relevance of this finding to onset of autoimmune diseases remains to be proven.
TO THE EDITOR
Atopic dermatitis (AD) is one of the most common inflammatory skin disorders characterized by pruritus, a chronically relapsing course and typically distributed lesions with dry skin, excoriations, and lichenification (Leung et al., 2004) . Topical treatment of acute lesions with corticosteroids (CS) is a mainstay in the therapy of the AD; however, long-term application is limited by CS-related side effects (e.g., skin atrophy) (Stoppolino et al., 1983) . The calcineurin inhibitors tacrolimus and pimecrolimus are now available as ointment/cream preparations and have proven to be a novel option for the topical treatment of AD (Ruzicka et al., 1997; Luger et al., 2001) . AD skin lesions harbor a variety of inflammatory cells, of which dendritic cells (DCs) represent a major fraction. Besides resident Langerhans cells and inflammatory dendritic epidermal cells, the presence of plasmacytoid DC (pDC) has recently been demonstrated in the dermis and less abundant in the epidermis of AD lesions (Wollenberg et al., 2002; Hashizume et al., 2005) . pDC are characterized by a plasma-cell-like morphology, a unique surface pheno-
, and the ability to produce large amounts of IFN-a, which assigns them a key role in innate antiviral immunity (Cella et al., 1999; Siegal et al., 1999) .
In prior studies, we have investigated the impact and mode of action of CS and pimecrolimus on the DC population in murine and healthy human and lesional AD skin and have reported divergent effects of these compounds on Langerhans cell viability and function (Hoetzenecker et al., 2004 (Hoetzenecker et al., , 2005 . In light of this finding, we asked whether these compounds also affect pDC. For this purpose, skin biopsies from a previous clinical trial were utilized (Hoetzenecker et al., 2005) . Briefly, 22 patients suffering from AD according to the diagnostic criteria of Hanifin and Rajka (Hanifin and Rajka, 1980; Rajka and Langeland, 1989) were assigned to treatment with 1% pimecrolimus cream (eight patients), matching vehicle cream (six patients), or 0.1% beta-methasone-17-valerate ((BMV), eight patients) in a 3-week, randomized, double-blind, vehiclecontrolled parallel-group clinical trial. Creams were applied twice daily to all affected areas of the skin (except face) and punch biopsies (4 mm) were taken from acute lesions before treatment (day 0; begin of study) and on day 21 (end of study) after initiation of therapy. The study was conducted according to the guidelines of the Declaration of Helsinki Principles, approved by the local ethics committee of the Medical University of Vienna (code numbers: EK303/2003 and EK355/2005) and a written informed consent was obtained from all patients. Immunoperoxidase staining against the pDC-specific marker BDCA-2 revealed substantial pDC numbers in the dermis of untreated AD skin lesions (3378 cells/mm 2 dermis; n ¼ 22), whereas pDC in normal healthy control skin were essentially absent (data not shown; n ¼ 5). As shown in Figure 1 , topical treatment with pimecrolimus and BMV for 21 days caused an almost complete disappearance of skin-infiltrating BDCA-2 þ cells by 94 and 95%, respectively, in comparison to vehicle-treated skin. The disappearance of BDCA-2 þ cells can be due to either the loss/downregulation of this marker on the responder cell or due to actual deletion/ destruction of pDC. In order to address this issue, pDC were isolated from peripheral blood of healthy adult volunteers ( Figure 2a ) and cultured with pimecrolimus and BMV at a concentration of 10 À6 mol/l (Figure 2b ). We have chosen this concentration intending to use the highest, non-toxic, biologically relevant dose for pimecrolimus to see an effect (Grassberger et al., 1999; Kalthoff et al., 2003) . At selected time points, cells were analyzed for marker expression and viability. Neither pimecrolimus nor BMV downmodulated the expression of BDCA-2 on pDC at any time point investigated (Figure 2b ). To prevent nonspecific binding of the anti-BDCA-2 mAb (Miltenyi Biotec Inc., Auburn, CA), it was mixed with 1% normal horse serum and 2% BSA and applied to sections (1 hour, room temperature). Immunolocalization of the primary antibody was performed using a biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA), followed by an avidin-biotinylated-HRP third layer (Vector Laboratories). AEC þ substrate (DakoCytomation, Glostrup, Denmark) were used as chromogen and sections were counterstained with Gill's hematoxylin (Santa Cruz Biotechnologies, Santa Cruz, CA However, we observed a marked reduction of BDCA-2 þ cells on BMV (92%), but not pimecrolimus (24%) culture already after 2 days when compared to vehicle (21%) ( Figure  2c ). After 7 days, pimecrolimus did not alter the viability of pDC when compared to vehicle (Figure 2c) . In contrast, pDC on BMV culture were all dead at this time point (not shown). From these data, we conclude that the disappearance of BDCA-2 þ cells in AD lesions upon CS treatment most likely results from a depletion of pDC. The mechanism responsible for their depletion in vivo remains to be investigated. In keeping with recent reports from others (Shodell et al., 2003; Suda et al., 2003; Abe and Thomson, 2006) , our data suggest that the reduction of pDC after topical treatment with CS may be owing to apoptosis. With regard to pimecrolimus, we have no evidence for direct effect on apoptosis in pDC in contrast to CS treatment. Theoretical possibilities are that indirect mechanisms such as cell migration and/or withdrawal of cytokines owing to an apoptosis-induced depletion of T cells upon pimecrolimus treatment (Hoetzenecker et al., 2005) may be responsible for their depletion.
It is well known that patients with AD have recurrent bacterial or viral skin infections. The reason for this particular susceptibility is not entirely understood. Recent evidence exists that these individuals have a defect in the production of natural antimicrobial peptides (Ong et al., 2002; Rieg et al., 2005) . Another reason could be a defect in other elements of the innate immune system. Indeed, pDC are less abundant in the infiltrate of AD lesions as compared to allergic contact eczema (Wollenberg et al., 2002; Bangert et al., 2003; Stary et al., 2005) . It will be interesting to see whether a functional defect of pDC may contribute to the high susceptibility of these patients to skin infections.
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We thank Drs G. . CS but not pimecrolimus strongly reduce pDC numbers in vitro. Buffy coats from peripheral blood of healthy adult volunteers were purchased from the local transfusion service (Rotes Kreuz, Vienna, Austria). Peripheral blood monocytes were isolated as interface cells after density gradient centrifugation (Lymphoprep; Axis-Shield, Rodelokka, Norway) and erythrocytes were removed with ammonium chloride (0.8% NH 4 Cl/0.1 mM EDTA). pDC (mean purity: 93.88%75.21 (n ¼ 4)) were isolated using a negative isolation kit according to the manufacturer's manual (Miltenyi Biotec Inc.). (a) Freshly isolated cells were stained for the indicated markers and 30,000 events/sample were acquired. pDC were cultured (5 Â 10 6 /ml) for the indicated time periods (day 2: n ¼ 3; day 7: n ¼ 1) in RPMI 1640 medium (GIBCO Life Technologies, Carlsbad, CA) supplemented with 10% FCS, 2 mM L-glutamine, antibiotics, and 10 ng/ ml recombinant human IL-3 (Pepro Tech, Rocky Hill, NJ) in the presence of vehicle, pimecrolimus, or BMV (all 10 À6 mol/l). Fluorescence was measured with a FACSCalibur flow cytometer, and data were analyzed using Cell Quest software (both Becton Dickinson, San Jose, CA). (b) Mean fluorescence intensity (MFI) was determined for BDCA-2 expression and (c) dead cells were identified by 7-amino-actinomycin D uptake (Sigma Chemicals Co., St Louis, MO).
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